Nuvation Bio
NUVB
160 hedge funds and large institutions have $526M invested in Nuvation Bio in 2024 Q4 according to their latest regulatory filings, with 29 funds opening new positions, 63 increasing their positions, 36 reducing their positions, and 22 closing their positions.
75% more repeat investments, than reductions
Existing positions increased: 63 | Existing positions reduced: 36
32% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 22
23% more capital invested
Capital invested by funds: $429M → $526M (+$97.4M)
4% more funds holding
Funds holding: 154 → 160 (+6)
2.69% more ownership
Funds ownership: 56.07% → 58.75% (+2.7%)
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
100% less call options, than puts
Call options by funds: $3K | Put options by funds: $952K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$41.3M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$12.7M |
| 3 |
LCM
Laurion Capital Management
New York
|
+$12.6M |
| 4 |
MB
MPM BioImpact
Boston,
Massachusetts
|
+$10.7M |
| 5 |
BlackRock
New York
|
+$4.04M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
-$44M |
| 2 |
OCA
Octagon Capital Advisors
New York
|
-$7.64M |
| 3 |
FLSM
Frazier Life Sciences Management
Palo Alto,
California
|
-$2.79M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$1.49M |
| 5 |
Renaissance Technologies
New York
|
-$1.19M |
NUVB Hedge Fund Activity: Q4 2024 in Review
160 of the 7,606 institutional investors tracked by Wall St. Rank reported a position in Nuvation Bio (NUVB) for Q4 2024, worth a combined $526M — up 23% from $429M a quarter earlier.
Buyers outnumbered sellers: 29 funds opened new NUVB positions and 22 closed out — a net gain of 7 holders — while 63 added to existing stakes and 36 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $41.3M. The largest seller was EcoR1 Capital, exiting entirely with an estimated $44M sold.
- 160 institutional investors held Nuvation Bio (NUVB) as of Q4 2024, up from 154 in Q3 2024.
- Funds reported $526M of Nuvation Bio stock for Q4 2024, up 23% quarter-over-quarter.
- 29 funds opened new Nuvation Bio positions in Q4 2024 and 22 closed out, a net change of +7 holders.
- The largest Nuvation Bio buyer in Q4 2024 was Fidelity Investments, an estimated $41.3M added.
- The largest Nuvation Bio seller in Q4 2024 was EcoR1 Capital, an estimated $44M sold.
Based on aggregated 13F filings for Q4 2024.